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Streptococcus pneumoniae serotype proﬁle (2007-2011)
Conclusion: Serotype 19A has become the most important
ause of IPD in children post-PCV7. Non-vaccine serotype 7F and
have also increased. Serotype 19A showed high penicillin non-
usceptibility (22%) and high occurrence of multi-drug resistance
39%) among the isolates.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.999
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Background: Inﬂuenza is a zoonotic disease that has caused
ajor epidemics in the world in both humans and animals caus-
ng economic losses. Inﬂuenza A/H1N1/2009 virus is circulating
mong human and animal populations. It is, therefore, important
o develop strategies to produce protective antibody responses
gainst H1N1 virus. There have been international efforts to obtain
nd a universal vaccine for different subtypes of the virus. Proteins
hat can be used to achieve this purpose are structural. So the aim
f this study was to obtain the M and NS1 recombinant proteins in
ddition to the HA1 of inﬂuenza virus strain A/H1N1/2009 (Paris
009) using baculovirus systems for used as vaccine and diagnostic
urposes
Methods: The genes M1, NS1, HA and NP inﬂuenza virus
/H1N1/Paris/2009 were ampliﬁed by RT-PCR and were subcloned
eparately into the vector pST-28 and subsequently cloned into
he pFastBac vector to obtain four recombinant baculovirus with
hich separately Sf9 insect cells were infected. Insect cells extracts
ere used to identify proteins by western blot using monoclonal
ntibodies and a pool of sera from people infected with the virus.
Results: In the western blot were recognized a protein of ∼26
Da (M protein), a ∼26 kDa (NS1 protein) and another of ∼65 kDa
HA1 protein). This monoclonal antibody using both patient sera
hereby demonstrated that these proteins retained their antigenic
roperties.Conclusion: We conclude that the baculovirus expression sys-
tem was efﬁcient for obtaining these four recombinant proteins of
inﬂuenzavirus. Theseproducts couldbeusedas immunogenand/or
reactive for ELISA test.
http://dx.doi.org/10.1016/j.ijid.2012.05.1000
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Adverse events following immunization from pandemic
inﬂuenza A (H1N1) - Laos 2010
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Background:After theﬁrst caseofpandemic InﬂuenzaA (H1N1)
in Laos in 2009, 978,390 high risk persons were vaccinated (preg-
nant women, chronically ill and health care workers). No ofﬁcial
and only 14 unofﬁcial reports of adverse events following immu-
nization (AEFI) were reported to the national passive surveillance
system. This triggeredan investigation into thequality andquantity
of adverse event reports in two provinces where patients received
pandemic vaccine with or without tetanus vaccine.
Methods: In November 2010, 1,204 persons from 73 randomly
selected villages in eight districts across Luangprabang and Savan-
nakhet provinces were interviewed about being at risk of inﬂuenza
complications andpost-vaccination symptoms.AEFIwasdeﬁnedas
any person receiving vaccine and any of the following symptoms
within threedays: report of fever, headache, nausea, local reactions,
myalgia, paralysis, shock, seizures or spontaneous abortion.
Results: Seventy-eight (6.5%) of 1,204 persons reported an AEFI
that met the case deﬁnition. No serious adverse events such as
seizure, shock, deathor abortionwere reported. 71% reportedmyal-
